Validation of a risk prediction model for COVID-19: the PERIL prospective cohort study.

Authors:
Mohammedain SA; Badran S; Elzouki AY; Salim H; Chalaby A and 8 more

Journal:
Future Virol

Publication Year: 2023

DOI:
10.2217/fvl-2023-0036

PMCID:
PMC10630949

PMID:
37970094

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Future Virol

Abbreviation: Future Virol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Virology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Antiviral attributes of bee venom as a possible therapeutic approach against SARS-CoV-2 infection.
Goswami S; Chowdhury JP. (2023) - Transparency Score: 2/6
CpG 684: an effective adjuvant for the inactivated COVID-19 vaccine in mice.
Liu J; Cang T; Jiang C and 7 more (2023) - Transparency Score: 2/6
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes.
Nag S; Mandal S; Mukherjee O and 2 more (2023) - Transparency Score: 3/6
Natural killer cells in COVID-19: from infection, to vaccination and therapy.
Zafarani A; Razizadeh MH; Pashangzadeh S and 3 more (2023) - Transparency Score: 2/6
Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient …
Horga A; Saenz R; Yilmaz G and 13 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests disclosure: The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties."

Evidence found in paper:

"Financial disclosure: This project was supported by the Qatar University Emergency Response Grant (QUERG-CENG-2020-1). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025